Background: Several studies have recently addressed the importance of glycemic variability (GV) in patients with acute coronary syndrome (ACS). Although daily GV measures, such as mean amplitude of glycemic excursions, are established predictors of poor prognosis in patients with ACS, the clinical significance of day-to-day GV remains to be fully elucidated. We therefore monitored day-to-day GV in patients with ACS to examine its significance. Methods: In 25 patients with ACS, glucose levels were monitored for 14 days using a flash continuous glucose monitoring system. Mean of daily differences (MODD) was calculated as a marker of day-to-day GV. N-terminal pro–brain natriuretic peptide (NT-proBNP) was evaluated within 4 days after hospitalization. Cardiac function (left ventricular end-diastolic volume, left ventricular ejection fraction, stroke volume) was assessed by echocardiography in the acute and chronic phases. Results: Of the 25 patients, 8 (32%) were diagnosed with diabetes, and continuous glucose monitoring (CGM)-based MODD was high (10.3 to 42.3) in 24 patients (96%). Although MODD did not correlate with max CK, there was a positive correlation between J-index, high blood glucose index, and NT-proBNP ( r =0.83, p <0.001; r =0.85, p <0.001; r =0.41, p =0.042, respectively). Conclusion: In patients with ACS, MODD was associated with NT-proBNP. These results suggest that monitoring day-to-day GV in ACS patients may be useful for evaluating worsening cardiac function independent of myocardial infarction after ACS.